Leiomyosarcoma Clinical Trials
Here are the 6 most popular medical studies for leiomyosarcoma
PARP Inhibitor
Combination Therapy with Cediranib, Olaparib, and Durvalumab for Advanced Solid Tumors
This trial is studying a combination of two drugs, olaparib and durvalumab or cediranib and durvalumab, in people with advanced cancer of the colon or rectum, pancreas, or uterus.
CAR T-cell Therapy
Cytotoxic T Cells for Relapsed EBV-positive Lymphoma
This trial is testing whether a new experimental therapy, third party LMP specific cytotoxic T lymphocytes (CTLs), can prevent or treat EBV Disorder including either Hodgkin Lymphoma or non-Hodgkin Lymphoma or Lymphoepithelioma or severe chronic active EBV infection syndrome (SCAEBV) or Leiomyosarcoma which has come back or has not gone away after treatment, including the best treatment.
Popular filter options for leiomyosarcoma trials
LMS Clinical Trials
View 29 LMS medical studies.
Chemotherapy
Unesbulin for Leiomyosarcoma
“ I have leiomyosarcoma for the second time. I received 35 round of radiation. After surgery on March 18. the cancer seemed to be gone. The radiation damaged my leg severely and the cancer came back. Along with breast cancer.”
Selective Inhibitor of Nuclear Export (SINE)
Selinexor Dosing Schedules for Sarcoma
This trial is testing a new drug, selinexor, for people with soft tissue sarcomas who have run out of other treatment options. Selinexor works by trapping proteins that would normally cause cancer cells to die, causing the cancer cells to die or stop growing.
Liposarcoma Clinical Trials
View 15 Liposarcoma medical studies.
Selective Inhibitor of Nuclear Export (SINE)
Selinexor Dosing Schedules for Sarcoma
This trial is testing a new drug, selinexor, for people with soft tissue sarcomas who have run out of other treatment options. Selinexor works by trapping proteins that would normally cause cancer cells to die, causing the cancer cells to die or stop growing.
Alkylating agents
Radiation Therapy +/- Combination Chemotherapy or Pazopanib for Soft Tissue Sarcomas
This trial is testing the combination of pazopanib, chemotherapy, and radiation therapy or radiation therapy alone to treat patients with non-rhabdomyosarcoma soft tissue sarcomas.
Virus Therapy
Nivolumab + BO-112 for Soft Tissue Sarcoma
This trial is testing the side effects of a combination of two drugs, one of which helps the body's immune system attack cancer cells, before surgery in patients with a type of cancer that can be removed surgically.
Metastatic Leiomyosarcoma Clinical Trials
View 32 metastatic leiomyosarcoma medical studies.
Chemotherapy
Unesbulin for Leiomyosarcoma
“ I have leiomyosarcoma for the second time. I received 35 round of radiation. After surgery on March 18. the cancer seemed to be gone. The radiation damaged my leg severely and the cancer came back. Along with breast cancer.”
Alkylating agents
Radiation Therapy +/- Combination Chemotherapy or Pazopanib for Soft Tissue Sarcomas
This trial is testing the combination of pazopanib, chemotherapy, and radiation therapy or radiation therapy alone to treat patients with non-rhabdomyosarcoma soft tissue sarcomas.
Phase 3 Leiomyosarcoma Clinical Trials
View 32 phase 3 leiomyosarcoma medical studies.
Chemotherapy
Unesbulin for Leiomyosarcoma
“ I have leiomyosarcoma for the second time. I received 35 round of radiation. After surgery on March 18. the cancer seemed to be gone. The radiation damaged my leg severely and the cancer came back. Along with breast cancer.”
Alkylating agents
Radiation Therapy +/- Combination Chemotherapy or Pazopanib for Soft Tissue Sarcomas
This trial is testing the combination of pazopanib, chemotherapy, and radiation therapy or radiation therapy alone to treat patients with non-rhabdomyosarcoma soft tissue sarcomas.
Leiomyosarcoma Clinical Trials With No Placebo
View 32 leiomyosarcoma medical studies that do not have a placebo group.
Selective Inhibitor of Nuclear Export (SINE)
Selinexor Dosing Schedules for Sarcoma
This trial is testing a new drug, selinexor, for people with soft tissue sarcomas who have run out of other treatment options. Selinexor works by trapping proteins that would normally cause cancer cells to die, causing the cancer cells to die or stop growing.
View More Leiomyosarcoma Trials
See another 13 many medical studies focused on leiomyosarcoma.
Frequently Asked Questions
Introduction to leiomyosarcoma
What are the top hospitals conducting leiomyosarcoma research?
In the realm of clinical trials for leiomyosarcoma, several esteemed hospitals are making significant strides in advancing treatment options for this rare form of cancer. One such institution is the University of Colorado Hospital located in Aurora. With four active leiomyosarcoma trials and a history that includes six completed studies, this hospital has been dedicated to tackling this challenging disease since its first recorded trial in 2012. Meanwhile, at Tampa's Moffitt Cancer Center, researchers are also conducting four ongoing clinical trials focused on leiomyosarcoma, building upon their initial trial recorded in 2014.
Moving north to Chicago, Northwestern University is actively engaged with four ongoing leiomyosarcoma trials as part of their impressive track record that encompasses nine previous investigations dating back to 1992. Over at Memorial Sloan Kettering Cancer Center in New Yorkf Colorado Hospital located in Aurora. With four active leiomyosarcoma trials and a history that includes six completed studies, this hospital has been dedicated to tackling this challenging disease since its first recorded trial in 2012. Meanwhile, at Tampa's Moffitt Cancer Center, researchers are also conducting four ongoing clinical trials focused on leiomyosarcoma, building upon their initial trial recorded in 2014.
Moving north to Chicago, Northwestern University is actively engaged with four ongoing leiomyosarcoma trials as part of their impressive track record that encompasses nine previous investigations dating back to 1992. Over at Memorial Sloan Kettering Cancer Center in New York City, a renowned medical facility globally recognized for its expertise, there are currently four active clinical trials targeting leiomyosarcoma while having conducted ten prior studies since recording their inaugural trial in 2001.
Lastly but notably not least UPMC based out Pittsburgh plays an important role as well; they have three ongoing examinations related to treating patients diagnosed with Leiomyoasracoma which displays strong dedication towards innovating more efficient solutions as these numbers add up alongside two earlier experiments registered only recently around until 2017.
Through the combined efforts of these reputable hospitals across different regions within the United States lies hope for individuals affected by leiomyosarcoma - a testament to how diverse healthcare institutions can unite under one purpose: improving outcomes and quality of life for those battling against this uncommon yet formidable form of cancer.
Which are the best cities for leiomyosarcoma clinical trials?
When it comes to leiomyosarcoma clinical trials, several cities emerge as top contenders for groundbreaking research opportunities. New York leads the pack with 17 active trials investigating treatments like Unesbulin, Dose Expansion Dose Level C (Cohort C), and VMD-928. Los Angeles follows closely behind with 11 ongoing studies focused on Doxorubicin, Unesbulin, Tabelecleucel, and other innovative approaches. Boston and Chicago also shine in this field, each boasting 11 active trials examining various treatment options such as Pembrolizumab and Lurbinectedin. Lastly, Jacksonville holds promise with its own set of 10 active trials exploring potential breakthroughs like L19TNF plus doxorubicin. These cities provide individuals battling leiomyosarcoma access to cutting-edge clinical trials that may shape the future of care for this disease.
Which are the top treatments for leiomyosarcoma being explored in clinical trials?
Clinical trials for leiomyosarcoma have showcased several promising treatments in recent years. Leading the pack is nivolumab, currently being explored in two active trials and making its debut in 2015. Also gaining traction is unesbulin, with one ongoing trial and two all-time leiomyosarcoma studies since its introduction in 2019. Rounding out this list is tabelecleucel, a newcomer on the scene that has already generated excitement with one active trial and a single all-time study since its listing in 2021. These innovative therapies are bringing renewed hope to patients fighting against leiomyosarcoma, paving the way towards more effective treatment options.
What are the most recent clinical trials for leiomyosarcoma?
Exciting advancements are being made in the field of leiomyosarcoma research, with several recent clinical trials offering potential treatment options for patients. One such trial focuses on unesbulin, a promising drug being evaluated in both Phase 2 and Phase 3 studies. Another trial examines the effectiveness of olaparib and temozolomide in treating leiomyosarcoma. Additionally, lurbinectedin is undergoing Phase 1 and Phase 2 testing to assess its potential benefits for patients with this type of sarcoma. Nanatinostat and OR2805 are also being investigated through combined Phase 1 and Phase 2 trials as possible treatments for leiomyosarcoma. These ongoing endeavors provide hope for improved outcomes and better quality of life for individuals battling this challenging disease.
What leiomyosarcoma clinical trials were recently completed?
Two recent clinical trials have brought valuable insights in the field of leiomyosarcoma research. In March 2017, OHSU Knight Cancer Institute conducted a pharmacological study to explore potential treatment options for this rare cancer. Another significant trial sponsored by Washingtont Cancer Institute conducted a pharmacological study to explore potential treatment options for this rare cancer. Another significant trial sponsored by Washington University School of Medicine investigated the use of Dexrazoxane and was completed in February 2016. These studies contribute to our understanding of leiomyosarcoma and pave the way for further advancements in its management and care.